Janssen Inc. et al. v. JAMP Pharma Corporation

Call to arrange a consultation

2024

T-48-24

Pending

6(1) PMNOC

Actions under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,671,357 (canagliflozin).

Counsel to:

JAMP Pharma Corporation

The decision is reported

Partner

Associate

Associate